| pubmed-article:8191595 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8191595 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:8191595 | lifeskim:mentions | umls-concept:C0278488 | lld:lifeskim |
| pubmed-article:8191595 | lifeskim:mentions | umls-concept:C0002475 | lld:lifeskim |
| pubmed-article:8191595 | lifeskim:mentions | umls-concept:C0078257 | lld:lifeskim |
| pubmed-article:8191595 | lifeskim:mentions | umls-concept:C0205132 | lld:lifeskim |
| pubmed-article:8191595 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:8191595 | pubmed:dateCreated | 1994-6-17 | lld:pubmed |
| pubmed-article:8191595 | pubmed:abstractText | Patients with metastatic breast carcinoma resistant to first line chemotherapy may require further treatment. Results o second line chemotherapy are still largely unsatisfactory. For this reason a phase II study on the combination of mitomycin C and vinorelbine was carried out. | lld:pubmed |
| pubmed-article:8191595 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8191595 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8191595 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8191595 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8191595 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8191595 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8191595 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8191595 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:8191595 | pubmed:issn | 0300-8916 | lld:pubmed |
| pubmed-article:8191595 | pubmed:author | pubmed-author:GebbiaNN | lld:pubmed |
| pubmed-article:8191595 | pubmed:author | pubmed-author:TestaAA | lld:pubmed |
| pubmed-article:8191595 | pubmed:author | pubmed-author:GebbiaVV | lld:pubmed |
| pubmed-article:8191595 | pubmed:author | pubmed-author:AgostaraBB | lld:pubmed |
| pubmed-article:8191595 | pubmed:author | pubmed-author:CusimanoM PMP | lld:pubmed |
| pubmed-article:8191595 | pubmed:author | pubmed-author:CallariA MAM | lld:pubmed |
| pubmed-article:8191595 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8191595 | pubmed:day | 28 | lld:pubmed |
| pubmed-article:8191595 | pubmed:volume | 80 | lld:pubmed |
| pubmed-article:8191595 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8191595 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8191595 | pubmed:pagination | 33-6 | lld:pubmed |
| pubmed-article:8191595 | pubmed:dateRevised | 2008-12-12 | lld:pubmed |
| pubmed-article:8191595 | pubmed:meshHeading | pubmed-meshheading:8191595-... | lld:pubmed |
| pubmed-article:8191595 | pubmed:meshHeading | pubmed-meshheading:8191595-... | lld:pubmed |
| pubmed-article:8191595 | pubmed:meshHeading | pubmed-meshheading:8191595-... | lld:pubmed |
| pubmed-article:8191595 | pubmed:meshHeading | pubmed-meshheading:8191595-... | lld:pubmed |
| pubmed-article:8191595 | pubmed:meshHeading | pubmed-meshheading:8191595-... | lld:pubmed |
| pubmed-article:8191595 | pubmed:meshHeading | pubmed-meshheading:8191595-... | lld:pubmed |
| pubmed-article:8191595 | pubmed:meshHeading | pubmed-meshheading:8191595-... | lld:pubmed |
| pubmed-article:8191595 | pubmed:meshHeading | pubmed-meshheading:8191595-... | lld:pubmed |
| pubmed-article:8191595 | pubmed:meshHeading | pubmed-meshheading:8191595-... | lld:pubmed |
| pubmed-article:8191595 | pubmed:meshHeading | pubmed-meshheading:8191595-... | lld:pubmed |
| pubmed-article:8191595 | pubmed:meshHeading | pubmed-meshheading:8191595-... | lld:pubmed |
| pubmed-article:8191595 | pubmed:meshHeading | pubmed-meshheading:8191595-... | lld:pubmed |
| pubmed-article:8191595 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8191595 | pubmed:articleTitle | Mitomycin "C" and vinorelbine as second line chemotherapy for metastatic breast carcinoma. | lld:pubmed |
| pubmed-article:8191595 | pubmed:affiliation | Servizio di Chemioterapia, Ospedale Oncologico M. Ascoli Palermo, Italy. | lld:pubmed |
| pubmed-article:8191595 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8191595 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8191595 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8191595 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8191595 | lld:pubmed |
